Thierry Andre

Thierry Andre is a leading European gastrointestinal oncologist who led the KEYNOTE-177 phase III trial demonstrating superior progression-free survival with pembrolizumab versus chemotherapy as first-line treatment for MSI-H/dMMR metastatic colorectal cancer. He has contributed extensively to clinical trial development in colorectal cancer including the IDEA collaboration defining optimal adjuvant treatment duration. He is a prolific clinical investigator with multiple landmark trials in colorectal and other gastrointestinal cancers. He has been a key opinion leader in incorporating biomarker-directed immunotherapy into standard practice.